Top Markets
Coin of the day
Incannex Healthcare Limited Incannex Healthcare Limited

Incannex Healthcare Limited

IHL
株式のランク #33836
Established in Melbourne, Australia, in 2001, Incannex Healthcare Limited,... Established in Melbourne, Australia, in 2001, Incannex Healthcare Limited, which operated as Impression Healthcare Limited until its rebranding in June 2020, is dedicated to the research, development, and commercialization of pharmaceutical products and therapies derived from medicinal cannabinoids and psychedelics. Its offerings include a trio of ultrapure cannabinoid compounds: APIRx-1801 (tetrahydrocannabinol), APIRx-1802 (CBD), and APIRx-1803 (cannabigerol). The company's clinical pipeline features IHL-42X, which has concluded Phase IIa trials for obstructive sleep apnea, and Psi-GAD, currently in Phase IIa development for generalized anxiety disorder. Other compounds having successfully advanced through Phase IIa clinical trials include CanChew Plus for irritable bowel syndrome, APIRx-1601 for vitiligo, APIRx-1602 for psoriasis, and APIRx-1603 for atopic dermatitis. Additionally, MedChew Dronabinol has completed Phase Ia trials for chemotherapy-induced nausea and vomiting. Its pre-clinical portfolio is extensive, including IHL-675A, which has completed studies for inflammatory lung disease, rheumatoid arthritis, and inflammatory bowel disease, alongside IHL-216A for traumatic brain injury/concussion. A broad array of further candidates are actively undergoing pre-clinical investigation, such as MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpetic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for Crohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for cannabis addiction, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, and APIRx-1702 for dry eye syndrome.
株価
$0.0270762
最終同期: 2023-11-30
時価総額
$6.78M
変化(1日)
-0.66%
変化(1年)
0.00%
AU
取引 Incannex Healthcare Limited (IHL)

カテゴリー

Incannex Healthcare Limited(IHL)のP/E比率
2026 時点のP/E比率 TTM 0
Incannex Healthcare Limited の最新の財務報告および株価によると、現在の P/E (TTM) は 0 です。2026 年末時点での P/E は 0 でした。
Incannex Healthcare Limited の P/E 比率の履歴(2026 〜 2026)
各年末のP/E比率
P/E比率 変化
提供された日付のデータは十分ではありません。
類似企業や競合他社のP/E比率
P/E比率の読み方

株価収益率(P/E Ratio)は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の(0に近い)P/Eは、損失が大きいことを示します。

P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。

10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。